Becton Dickinson and Co (BDX) Stake Lessened by Mawer Investment Management Ltd.

Share on StockTwits

Mawer Investment Management Ltd. lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 21.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,348,194 shares of the medical instruments supplier’s stock after selling 369,185 shares during the period. Becton Dickinson and comprises 2.4% of Mawer Investment Management Ltd.’s holdings, making the stock its 10th largest holding. Mawer Investment Management Ltd.’s holdings in Becton Dickinson and were worth $336,689,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its stake in Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 6,545,502 shares during the last quarter. Ronna Sue Cohen raised its stake in Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after buying an additional 5,710,365 shares during the last quarter. Norges Bank bought a new position in Becton Dickinson and during the fourth quarter worth $515,703,000. Mackenzie Financial Corp raised its stake in Becton Dickinson and by 27.7% during the fourth quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock worth $437,966,000 after buying an additional 421,825 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after buying an additional 416,459 shares during the last quarter. 84.60% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on the stock. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Piper Jaffray Companies lifted their target price on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. UBS Group lowered their target price on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. Wells Fargo & Co lowered their target price on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research note on Monday, May 13th. Finally, BMO Capital Markets lowered their target price on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research note on Friday, May 10th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $255.31.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 3,123 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the sale, the chief executive officer now directly owns 215,372 shares in the company, valued at $54,926,321.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 8,309 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the completion of the sale, the chief executive officer now owns 222,785 shares of the company’s stock, valued at $56,839,137.05. The disclosure for this sale can be found here. Insiders sold 36,129 shares of company stock valued at $8,836,315 over the last 90 days. Corporate insiders own 0.12% of the company’s stock.

NYSE:BDX opened at $234.16 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $63.44 billion, a price-to-earnings ratio of 21.27, a P/E/G ratio of 1.76 and a beta of 1.16. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business’s quarterly revenue was down .6% on a year-over-year basis. During the same period last year, the company posted $2.65 earnings per share. As a group, research analysts anticipate that Becton Dickinson and Co will post 11.69 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s payout ratio is 27.97%.

ILLEGAL ACTIVITY WARNING: “Becton Dickinson and Co (BDX) Stake Lessened by Mawer Investment Management Ltd.” was originally reported by Equities Focus and is the property of of Equities Focus. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.equitiesfocus.com/2019/05/29/becton-dickinson-and-co-bdx-stake-lessened-by-mawer-investment-management-ltd.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: How does new data get added to a blockchain?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.